staff reporter

News items for the weeks of Nov. 21 and Nov. 28, 2022.

The first-in-human studies of the anti-EDB candidate PYX-201 and immunotherapy candidate PYX-106 are expected to begin in early 2023.

Regulators simultaneously approved a companion diagnostic from Abbott to identify relapsed or refractory acute myeloid leukemia patients eligible for Rezlidhia.

The agent, ¹⁸F-FAPI-74, is designed to detect FAP-expressing tumors with PET imaging, including colorectal, pancreatic, liver, bile duct, and gastric cancers.

Researchers examined genetic, tumor mutation, and immune features among individuals surviving at least a decade after an advanced ovarian cancer diagnosis.

The company will use the funds from Pfizer and the financing proceeds to further develop its lead candidate samuraciclib in breast cancer and other tumor types.

In the SPARK study, researchers will try to link resistance mechanisms and treatment outcomes in patients who have progressed on a KRAS G12C inhibitor.

Erasca has already collaborated with Pfizer to study the combination in the US and Canada, but the new agreement allows the firm to expand the study internationally.

The company also announced the conversion of existing convertible notes and convertible preferred shares.

Researchers will employ the company's tumor-informed, personalized assays to analyze ctDNA patterns linked to immunotherapy drug response.